Q3 Net Loss Narrows to $3.0M as HeartBeam Cuts Cash Burn and Extends Runway Into 2027
BEAT is trading near its 52-week low of $0.355 (14% above the low) on light trading volume (0.1× avg).
Summary
HeartBeam reported a Q3 2026 net loss of $3.0 million, or $(0.05) per share, versus $5.3 million, or $(0.15) per share, a year earlier, as total operating expenses fell to $3.5 million from $5.3 million. Cash stood at $6.1 million on September 30; including roughly $4.0 million raised through the ATM in Q4, pro forma cash is about $10.1 million. Management narrowed full-year 2026 operating cash outflow guidance to $12.0-$12.5 million and expects the runway to extend further into 2027. The company is now fully focused on heart attack assessment: it has FDA Breakthrough Device Designation, TAP acceptance, and alignment on a 510(k) pathway, with the U.S. pivotal study design due in Q4 2026 and enrollment starting Q1 2027. The cash position remains thin relative to the pivotal study ahead, so the ATM remains the funding lever to watch.
At the time of this announcement, BEAT was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.8M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.